STAT1 antibody

Synonyms:ISGF 3 antibody, STAT1 antibody, STAT91 antibody
Catalogue No.:FNab09985Reactivity:Human, Rat
Host:RabbitTested Application:ELISA, WB, IHC
Clonality:polyclonalIsotype:IgG
  • SPECIFICATIONS
Product Name
STAT1 antibody
Catalogue No.
FNab09985
Size
100μg
Form
liquid
Purification
Immunogen affinity purified
Purity
≥95% as determined by SDS-PAGE
Clonality
polyclonal
Isotype
IgG
Storage
PBS with 0.02% sodium azide and 50% glycerol pH 7.3, -20℃ for 12 months(Avoid repeated freeze / thaw cycles.)
Immunogen
Immunogen
signal transducer and activator of transcription 1, 91kDa
Alternative Names
ISGF 3 antibody, STAT1 antibody, STAT91 antibody
UniProt ID
P42224
Observed MW
84 kDa
Application
Tested Applications
ELISA, WB, IHC
Recommended dilution
WB: 1:500-1:2000; IHC: 1:50-1:500
Validated Images
Rat liver tissue were subjected to SDS PAGE followed by western blot with FNab09985(STAT1 antibody) at dilution of 1:1000
Immunohistochemistry of paraffin-embedded human breast cancer tissue slide using FNab09985(STAT1 Antibody) at dilution of 1:200
Background
Signal transducer and transcription activator that mediates cellular responses to interferons(IFNs), cytokine KITLG/SCF and other cytokines and other growth factors. Following type I IFN(IFN-alpha and IFN-beta) binding to cell surface receptors, signaling via protein kinases leads to activation of Jak kinases(TYK2 and JAK1) and to tyrosine phosphorylation of STAT1 and STAT2. The phosphorylated STATs dimerize and associate with ISGF3G/IRF-9 to form a complex termed ISGF3 transcription factor, that enters the nucleus. ISGF3 binds to the IFN stimulated response element(ISRE) to activate the transcription of IFN-stimulated genes(ISG), which drive the cell in an antiviral state. In response to type II IFN(IFN-gamma), STAT1 is tyrosine-and serine-phosphorylated. It then forms a homodimer termed IFN-gamma-activated factor(GAF), migrates into the nucleus and binds to the IFN gamma activated sequence(GAS) to drive the expression of the target genes, inducing a cellular antiviral state. Becomes activated in response to KITLG/SCF and KIT signaling. May mediate cellular responses to activated FGFR1, FGFR2, FGFR3 and FGFR4.